Clinical application of protein induced by vitamin K antagonist-II as a biomarker in hepatocellular carcinoma
- 13 October 2016
- journal article
- review article
- Published by Springer Nature in Tumor Biology
- Vol. 37 (12) , 15447-15456
Abstract
Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide. Early diagnosis improves the prognosis. Protein induced by vitamin K antagonist-II (PIVKA-II) is an effective serum biomarker for HCC diagnosis and prognosis. Combined with another serum biomarker α-fetoprotein (AFP), the sensitivity and specificity of HCC diagnosis can be improved to a maximum of 94 and 98.5 %, respectively. PIVKA-II alone or in combination with AFP and/or AFP-L3 was effective in predicting the treatment response and clinical outcome of curative hepatic resection, chemotherapy, targeted therapy, radiotherapy, and liver transplantation. Japanese clinical guidelines recommend the combined use of PIVKA-II and AFP for the diagnosis of HCC, management of high-risk population, and prognosis of anticancer treatment. Further, PIVKA-II as a functional target promoted HCC cell proliferation, invasion, and metastasis by activating c-Met and other signal transduction pathways. Inhibition of PIVKA-II may provide a selective and effective therapy for HCC.Keywords
Funding Information
- National Natural Science Foundation of China (81372262, 81472284, 81172020)
- Program for Excellent Young Scholars of SMMU and Charitable Project on Scientific Research of Shanghai (N/A)
This publication has 84 references indexed in Scilit:
- Evaluation of Individual and Combined Applications of Serum Biomarkers for Diagnosis of Hepatocellular Carcinoma: A Meta-AnalysisInternational Journal of Molecular Sciences, 2013
- Diagnostic performance of alpha-fetoprotein, lens culinaris agglutinin-reactive alpha-fetoprotein, des-gamma carboxyprothrombin, and glypican-3 for the detection of hepatocellular carcinoma: a systematic review and meta-analysis protocolSystematic Reviews, 2013
- Prognostic significance of a combination of pre- and post-treatment tumor markers for hepatocellular carcinoma curatively treated with hepatectomyJournal of Hepatology, 2012
- Novel method to measure serum levels of des‐gamma‐carboxy prothrombin for hepatocellular carcinoma in patients taking warfarin: A preliminary reportCancer Science, 2012
- Des-γ-carboxyl prothrombin induces matrix metalloproteinase activity in hepatocellular carcinoma cells by involving the ERK1/2 MAPK signalling pathwayEuropean Journal of Cancer, 2011
- Management of Hepatocellular Carcinoma: An Update ΔσHepatology, 2011
- Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinomaHepatology International, 2010
- Des-γ-carboxy prothrombin stimulates human vascular endothelial cell growth and migrationClinical & Experimental Metastasis, 2009
- Clinical Evaluation of Lens Culinaris Agglutinin-Reactive α-Fetoprotein and Des-γ-Carboxy Prothrombin in Histologically Proven Hepatocellular Carcinoma in the United StatesDigestive Diseases and Sciences, 2007
- Des-γ-Carboxy (Abnormal) Prothrombin as a Serum Marker of Primary Hepatocellular CarcinomaNew England Journal of Medicine, 1984